Roche ’818 patent
This article was originally published in The Gray Sheet
U.S. Patent and Trademark Office will reexamine Roche's Thermus aquaticus (Taq) DNA polymerase patent to "determine whether any prior art cited in recent litigation poses any new question of patentability," the firm announces April 12. The enforceability of the patent is currently under review by the U.S. Court of Appeals in Washington, D.C. after being challenged by Promega Corp. (1"The Gray Sheet" Dec. 13, 1999, p. 16)...
You may also be interested in...
Roche Molecular Systems and parent company Hoffman-La Roche intend to appeal a Dec. 7 San Francisco federal district court ruling that the firm's native Taq polymerase patent is "unenforceable" because of inequitable conduct during Cetus Corp.' s patent application process in 1986, Roche said Dec. 8.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.